PLoS ONE (Jan 2023)

Peptide immunization against the C-terminal of alpha-synuclein reduces locomotor activity in mice overexpressing alpha-synuclein.

  • Yu-Sung Chiu,
  • Kuo-Jen Wu,
  • Seong-Jin Yu,
  • Kun-Lieh Wu,
  • Yu-Syuan Wang,
  • Jing Lin,
  • Chia-Ying Chu,
  • Shuchun Chen,
  • Hsi Chen,
  • Shu-Ching Hsu,
  • Yun Wang,
  • Yun-Hsiang Chen

DOI
https://doi.org/10.1371/journal.pone.0291927
Journal volume & issue
Vol. 18, no. 9
p. e0291927

Abstract

Read online

Abnormal accumulation of alpha-synuclein (αSyn) in the remaining nigra dopaminergic neurons is a common neuropathological feature found in patients with Parkinson's disease (PD). Antibody-based immunotherapy has been considered a potential approach for PD treatment. This study aims to investigate the effectiveness of active immunization against αSyn in a mouse model of PD. Adult mice were immunized with or without a synthetic peptide containing the C-terminal residues of human αSyn and activation epitopes, followed by an intranigral injection of adeno-associated virus vectors for overexpressing human αSyn. Upon the peptide injection, αSyn-specific antibodies were raised, accompanied by degeneration of dopaminergic neurons and motor deficits. Furthermore, the induction of neuroinflammation was postulated by the elevation of astroglial and microglial markers in the immunized mice. Instead of lessening αSyn toxicity, this peptide vaccine caused an increase in the pathogenic species of αSyn. Our data demonstrated the potential adverse effects of active immunization to raise antibodies against the C-terminal fragment of αSyn. This drawback highlights the need for further investigation to weigh the pros and cons of immunotherapy in PD. Applying the αSyn C-terminal peptide vaccine for PD treatment should be cautiously exercised. This study provides valuable insights into the intricate interplay among immune intervention, αSyn accumulation, and neurodegeneration.